drugset
Drugs / jCell
last change Sep 2026 re-read 3 minutes ago

jCell

Cell therapy

Developed for
retinitis pigmentosa
Investigated by
jCyte, Inc

Trials 1

today NCT06912633 · Ph 2
2026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06912633 Jun 2025 → Sep 2026 overdue retinitis pigmentosa jCyte, Inc Recruiting No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2024-02-21 jCyte, Inc jCyte Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell® for Retinitis Pigmentosa in The Second Half of 2024 jcyte.com ↗
2021-11-15 jCyte, Inc jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy jcyte.com ↗
2021-05-03 jCyte, Inc jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy jcyte.com ↗
2020-05-08 jCyte, Inc jCyte Enters into Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical jcyte.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as jCell “Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)” NCT06912633 ↗
Modality Cell therapy “human retinal progenitor cells” NCT06912633 ↗
Route Intravitreal “Single intravitreal injection of 6.0 million retinal progenitor cells (RPCs)” NCT06912633 ↗